Clinical Trial: CoQ10 and D-ribose in Patients With Diastolic Heart Failure
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose
Brief Summary: The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
Detailed Summary:
Sponsor: University of Kansas Medical Center
Current Primary Outcome: Change in health status of patients with HFpEF [ Time Frame: Change from Baseline to Week 12 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Change in vigor [ Time Frame: Change from Baseline to Week 12 ]Change will be measured using the the Vigor subscale from the Profile of Mood States (POMS) questionnaire.The subscale has 8 questions. Scores for the subscale range from 0-32, in which higher scores reflect more vigor.
- Left ventricular diastolic function [ Time Frame: Change from Baseline to Week 12 ]Change will be measured using advanced echocardiographic imaging.
- Change in 6 minute walk test (6MWT) [ Time Frame: Change from Baseline to Week 12 ]The 6-minute walking test (6MWT) is a simple test. Test measures the total distance in meters a person can walk in 6 minutes.
- Change in venous blood B-type natriuretic peptide (BNP) levels [ Time Frame: Change from Baseline to Week 12 ]BNP concentration will be measured.
- Change in lactate/adenosine triphosphate (ATP) ratio [ Time Frame: Change from Baseline to Week 12 ]The lactate/ATP ratio will be measured for each participant.
Original Secondary Outcome: Same as current
Information By: University of Kansas Medical Center
Dates:
Date Received: April 25, 2017
Date Started: November 2017
Date Completion: March 2020
Last Updated: April 25, 2017
Last Verified: April 2017